Charles Schwab Investment Management Inc Fennec Pharmaceuticals Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 61,287 shares of FENC stock, worth $503,779. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,287

Previous 61,146 0.23%

Holding current value

$503,779

Previous $372,000 36.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$5.01 - $8.4 $706 - $1,184	141 Added 0.23%	61,287 $508,000
Q1 2025 Sep 15, 2025	SELL	$5.54 - $7.02 $781 - $989	-141 Reduced 0.23%	61,146 $372,000
Q4 2024 Feb 06, 2025	BUY	$3.99 - $6.37 $22,719 - $36,270	5,694 Added 10.27%	61,146 $386,000
Q2 2024 Aug 12, 2024	BUY	$6.02 - $10.99 $84,009 - $153,365	13,955 Added 33.63%	55,452 $338,000
Q2 2023 Aug 09, 2023	BUY	$7.27 - $9.82 $301,683 - $407,500	41,497 New	41,497 $366,000
Q2 2021 Aug 16, 2021	SELL	$5.96 - $7.85 $273,385 - $360,079	-45,870 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.99 - $8.55 $17,251 - $24,624	2,880 Added 6.7%	45,870 $342,000
Q3 2020 Nov 13, 2020	SELL	$5.19 - $10.17 $18,652 - $36,550	-3,594 Reduced 7.72%	42,990 $261,000
Q2 2020 Aug 14, 2020	BUY	$5.43 - $9.39 $252,951 - $437,423	46,584 New	46,584 $389,000
Q2 2019 Aug 09, 2019	SELL	$3.3 - $5.09 $89,796 - $138,503	-27,211 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$4.64 - $7.58 $28,355 - $46,321	6,111 Added 28.96%	27,211 $132,000
Q2 2018 Aug 08, 2018	BUY	$10.05 - $14.33 $212,055 - $302,363	21,100 New	21,100 $221,000

Others Institutions Holding FENC

# of Institutions

Shares Held

14M

Call Options Held

10K

Put Options Held

83.8K

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $214M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Fennec Pharmaceuticals Inc. Transaction History